Chimeric antigen receptor (CAR)- expressing natural killer cells (NK-92) for the treatment of ErbB2-positive amalignancies
Prof. Torsten Tonn, MD
Transfusion Medicine, TU Dresden Germany
Torsten Tonn, holds the chair for Transfusion Medicine at the Medical Faculty Carl Gustav Carus, Technical University Dresden (Germany) and is medical director (CEO) of the German Red Cross Blood
Donation Service North/East. Prior to this, Torsten Tonn worked 15 years at the department for Transfusion Medicine, University Hospital Frankfurt/M, where he was head of the apheresis and cell & gene therapy unit. His scientific focus has been to facilitate the transfer of cell based therapies into clinical applications. He pioneered first in human clinical trials using the off-the-shelf- NK cell line NK-92 and together with Winfried Wels (Frankfurt/Germany) furhter engineered them to express tumor specific antigen receptors (CARs). Moreover he translated Streptamer-based cell isolation processes for antigen specific donor T lymphocytes into clinical practice. Torsten Tonn served in many committees, among them the cell based product working party (CPWP) of the CAT (European Medicines Agency, EMA).
Host: Hannes Stockinger